Newsletter

Perfect Sugar Substitute: Health Sciences Has It

July 30, 2005
Volume VI, Issue 68
Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com

To OTC Journal Members:
 

Comments in the BLOG

I'll probably do a BLOG posting about an hour into the trading day on Monday with some technical thoughts on today's idea. I expect this stock to trade very well over the next several weeks, and it's important to own it right. Check the home page or your Yahoo! rss feed about an hour into the trading day for some commentary. Last week there were BLOG postings on the 1960 Presidential Election and the ugly turn of events at HyperDynamics (HDY).

To use the BLOG, simply go to the home page at www.otcjournal.com - the BLOG will scroll down automatically on the right side of your screen. The most current journal entries appear in the middle of your screen. Check back frequently for updates particularly when stocks are moving to overbought or oversold levels or in volatile markets. Your questions and postings do not automatically appear, so don't bother posting the same question multiple times. I personally go through to moderate and respond to every question.
 

Health Sciences Group (OTC BB: HESG); Two Bockbuster Products

Obesity is an epidemic in the United States today. The US Government considers anyone with a BMI (body mass index) of 30 or more to be obese. That includes 61.3 million Americans.

The weight control industry has evolved into a behemoth; $40 billion is spent annually in the US alone on weight control products and programs.

Public Enemy #1 in the fight against fat is one of our favorite foods: SUGAR. Sugar is used to enhance the flavor of more things than you can imagine. Aside from the obvious like pastries, candy, and soft drinks, vast amounts of refined sugar are found in products like ketchup and bread.

Refined Sugar, the ultimate "Bad Carb", has a number of nasty side effects. It is poison to diabetics. It causes your metabolism to spike briefly (a glycemic effect) and then crash. Kids run around the house destroying everything in their paths. You feel energized, then tired. You want more to feel energized again. Net result: Excess pounds.

Here's an overview of current substitutes:

  • Aspertame (Sweet n Low, Equal) was the most widely accepted sugar substitute. Aspertame is 100% chemical, has an unpleasant after taste, and has lost ground to Sucralose (Splenda) in recent years.
  • Sucralose (Splenda), was approved for use as a sugar substitute by the FDA in 1998. It tastes like sugar but is 600 times as sweet. It has no calories. It is derived from the sugar molecule and combined with Chlorine. It doesn't blend well with other substances, and cannot be used by itself in baking. It has been associated with numerous negative side effects including swelling of the liver and kidneys and shrinkage of the thymus: a gland that is the very foundation of our immune system.
  • Stevia: Zero calories and all natural, but has rough taste. It does not have a GRAS (Generally Recognized as Safe) rating from the FDA.
Shugr™

Health Sciences Group has the answer. Shugr™. Shugr™ is the ultimate sugar substitute. Zero calories, zero carbs, tastes exactly like sugar, bakes and mixes exactly like sugar, and is made from 99.5% natural ingredients.

Shugr™ is derived from a blend of erythritol and tagatose which occurs naturally in many fruits and vegetables. Shugr™ has a patent pending and its ingredients have a GRAS (Generally Recognized as Safe) designation for food safety as determined by the U.S. FDA.

The product is currently being sold through several national chains including the Vitamin Shoppe and GNC. At present, it is only available in 1.3 lb jars, but packaging is expanding as you see here. The larger quantities will come in bags for baking just like regular sugar, and packets will be offered as well for individual servings.

The health stores represent a vibrant market for the product, but much higher volume potential exists as an additive to an end product. Recently, HESG signed a distribution arrangement with DNP International, one of the largest suppliers of ingredients to food manufacturers. DNP sold 8 million lbs of vitamin C in 2004.

DNP will be moving Shugr™ into a far larger market- as an ingredient for baked goods and beverages. This market is huge, and the sales cycle is long. Food producers do extensive testing with new ingredients before substituting in existing formulas.
 

Sequestrol™

HESG has another blockbuster product roll out scheduled for later this year. They have obtained the world wide rights to market Sequestrol™. Sequestrol™ is a nutritional supplement that has been clinically proven to lower cholesterol. It was developed in Korea, and is extracted from seaweed.

In a study conducted on 57 subjects, Sequestrol™ reduced serum cholesterol levels by 22.7% after 30 days of oral administration with no change in diet.

In an similar animal trial, Sequestrol™ was found to reduce LDLs (the bad cholesterol) by 59% and 75%, while increasing levels of HDL (the good cholesterol).

Sequestrol™ is a white powder that is odorless and tasteless. It has a huge advantage over the avastatin drugs (Lipitor, et. al.) in that it is 100% natural, and can be combined with food products. It is also about 1/4th the price of the statin drugs.

Sequestrol™ can be combined with foods, and HESG anticipates manufacturers will be able to claim their product lowers cholesterol.

More immediately, HESG is slated to go into production on an infomercial to directly market the product. Sequestrol™ will be sold by informercial in a nationwide roll out later this fall.
 

Conclusion

HESG management is focusing nearly all of it's sales efforts over the next 6 months on Shugr™ and Sequestrol™. These are two clinically proven products that have enormous market potential. A natural sugar substitute that tastes and bakes exactly like sugar. Just follow the recipe, and substitute Shugr™. Combine the sugar substitute with a natural cholesterol reducer that can be added to foods and beverages - two very high profile products. Once these are successfully launched, there are others in the pipeline.

Here a six reasons to own HESG today:

  • Technically, the stock looks outstanding. After making a new all time high back in February, the stock pulled back to a low of just under $.70 last June, and has been making a series of higher lows and higher highs since then. HESG has been slowly working its way up through this trading range since mid May, and appears ready to break out. The consolidation pattern is circled in blue.
  • The stock is trading 40% below the high set last February.
  • August is the best time of the year to accumulate positions for a three to six month investment. Last year, the OTC Journal had several doubles and triples between mid August and year's end.
  • The company is launching two new products with blockbuster potential, and sales should ramp up as these products become more widely known.
  • There is a big pipeline of new products coming as soon as the initial two are launched.
  • The market capitalization is only in the $20 million range, leaving lots of upside potential. As sales ramp up, I could easily see this stock trading in the $50 million market cap range.
Peter Lynch, considered by many to be the greatest mutual fund manager of all time, believed in investing in companies with products and services that he used and understood.

For Sequestrol™ it's pretty easy to see the benefits of a clinically proven cholesterol reducing powder that can be blended with anything. Pfizer's Liptor is the highest selling drug on planet earth.

I have two 1.3lb jars of Shugr™ sitting on my counter, and have it every morning on my cereal. It is an outstanding product. No sugar substitute comes close. But, don't take my word for it. Do what Peter Lynch would do. Try it yourself.

I convinced the management at HESG to offer a free sample to OTC Journal members. All you have to do is go to a web page, help HESG out by clicking a few buttons in a survey, and give them your address. They will send you a free sample.

Simply Click Here, or copy and paste the following URL into your browser: http://www.healthsciencesgroup.com/free_shugr.asp. While you are there, check out the company's web site.

I like this stock to go back to it's previous high of $1.50 before year's end, which would result in a 67% return on invested capital. Much, much higher levels could be attained down the road if Shugr™ and Sequestrol™ find their way into the recipes of household name foods and beverages.

Splenda did it, and hands down Shugr™ is simply a better product.

More details on sales projections and margins in future editions. I will have a BLOG posting up on Monday morning on HESG, so you can post any questions you have there.


Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Subscribe Here

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.


Disclaimer
The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features.  Likewise, this newsletter is owned by MarketByte, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. Health Sciences Group, Inc has paid MarketByte LLC as fee of $25,000 in cash, 200,000 newly issued restricted shares, and 200,000 warrants convertible at $.88 for ongoing coverage of the company.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. 

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services. 

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $140,0000 in Dutchess Private Equities II LP (“the Dutchess Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner.  No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Dutchess Limited Partnership.  The Dutchess Limited Partnership is one of two hedge funds managed by Dutchess Advisors.  Dutchess Advisors periodically refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter.  Dutchess Advisors may or may not own shares in the companies that it so refers to MarketByte.  MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Dutchess Advisors owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 3525 Del Mar Heights Rd #334, San Diego, CA 92130.


Unsubscribe Here

You can unsubscribe from this list at any time by Clicking Here and HITTING SEND. If you are having difficulty removing yourself or wish to change your address please go to http://listserv.otcjournal.com/opt.cgi?.

 
 
 

Disclaimer

The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies and receives compensation from them or third parties as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer’s securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.

All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.finra.org. We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the express written consent of the editors of otcjournal.com.

UNSUBSCRIBE

You can unsubscribe from this list at any time by Clicking Here. If you are having difficulty removing yourself or wish to change your address please go to http://www.otcjournal.com/opt/.